These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22517270)

  • 21. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parametric latent class joint model for a longitudinal biomarker and recurrent events.
    Han J; Slate EH; Peña EA
    Stat Med; 2007 Dec; 26(29):5285-302. PubMed ID: 17542002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers.
    Zhao L; Feng D; Neelon B; Buyse M
    Stat Med; 2015 May; 34(10):1733-46. PubMed ID: 25630845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
    Kamiya N; Suzuki H; Nishimura K; Fujii M; Okegawa T; Matsuda T; Morita T; Takihana Y; Ozono S; Namiki M; Matsubara A; Ichikawa T; Miki T
    Jpn J Clin Oncol; 2014 Mar; 44(3):263-9. PubMed ID: 24516203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Backward joint model and dynamic prediction of survival with multivariate longitudinal data.
    Shen F; Li L
    Stat Med; 2021 Sep; 40(20):4395-4409. PubMed ID: 34018218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
    Vickers AJ; Savage C; O'Brien MF; Lilja H
    J Clin Oncol; 2009 Jan; 27(3):398-403. PubMed ID: 19064972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts.
    Proust-Lima C; Taylor JM; Williams SG; Ankerst DP; Liu N; Kestin LL; Bae K; Sandler HM
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):782-91. PubMed ID: 19014779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flexible joint model for multiple longitudinal biomarkers and a time-to-event outcome: With applications to dynamic prediction using highly correlated biomarkers.
    Li N; Liu Y; Li S; Elashoff RM; Li G
    Biom J; 2021 Dec; 63(8):1575-1586. PubMed ID: 34272887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Joint modelling of longitudinal and time-to-event data: an illustration using CD4 count and mortality in a cohort of patients initiated on antiretroviral therapy.
    Mchunu NN; Mwambi HG; Reddy T; Yende-Zuma N; Naidoo K
    BMC Infect Dis; 2020 Mar; 20(1):256. PubMed ID: 32228483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.
    Preisser F; Bandini M; Nazzani S; Mazzone E; Marchioni M; Tian Z; Chun FKH; Saad F; Briganti A; Haese A; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Eur Urol Oncol; 2020 Oct; 3(5):631-639. PubMed ID: 31411975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.
    Król A; Ferrer L; Pignon JP; Proust-Lima C; Ducreux M; Bouché O; Michiels S; Rondeau V
    Biometrics; 2016 Sep; 72(3):907-16. PubMed ID: 26890381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A latent class approach for joint modeling of a time-to-event outcome and multiple longitudinal biomarkers subject to limits of detection.
    Li M; Lee CW; Kong L
    Stat Methods Med Res; 2020 Jun; 29(6):1624-1638. PubMed ID: 31469042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint analysis of left-censored longitudinal biomarker and binary outcome via latent class modeling.
    Li M; Kong L
    Stat Med; 2018 Jun; 37(13):2162-2173. PubMed ID: 29611202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Prostate Cancer Recurrence After Radical Prostatectomy.
    Jeffers A; Sochat V; Kattan MW; Yu C; Melcon E; Yamoah K; Rebbeck TR; Whittemore AS
    Prostate; 2017 Feb; 77(3):291-298. PubMed ID: 27775165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pattern mixture models and latent class models for the analysis of multivariate longitudinal data with informative dropouts.
    Dantan E; Proust-Lima C; Letenneur L; Jacqmin-Gadda H
    Int J Biostat; 2008; 4(1):Article 14. PubMed ID: 22462120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint partially linear model for longitudinal data with informative drop-outs.
    Kim S; Zeng D; Taylor JM
    Biometrics; 2017 Mar; 73(1):72-82. PubMed ID: 27479944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On longitudinal prediction with time-to-event outcome: Comparison of modeling options.
    Maziarz M; Heagerty P; Cai T; Zheng Y
    Biometrics; 2017 Mar; 73(1):83-93. PubMed ID: 27438160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.